Valuing ResApp Health, page-423

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #

First 423 Last

Share
Profile

Follow
Taurean7

1,772 Posts.

3102

11/08/22

12:01

Post #: 63053980
Share

Originally posted by bMAKE ↑

Further to my post earlier. I spoke extensively with Phillip from Georgeson this morning. He asked me if I was happy with the recent increase to the offer price. I said yes I'm happy to see the price lifted from 14.6 cents to 20.8 cents, however I've maintained our "No" votes on all 3 accounts to resolution 2 (takeover). I also discussed with him about the market credibility of the IER because of the tier 3 firm who conducted the analysis and valuation. There are question marks around whether they had sufficient capabilities and expertise to deliver a quality IE valuation and output that meets the benchmark standards set by tier 1 firms.

Phillip can see my professional credentials so we had an in-depth discussion around what might be my professional opinion around an underlying value that reasonably captures both the current state & reasonable future state of RAP. In a nutshell, 40 to 50 cents a share range should be the middle ground where RAP's current premium has been priced in, all holders S/T or L/T are winning. Yet plenty of headroom and ceiling for Pfizer to invest its expertise to extract further value from RAP acquisition and generate a positive M&A NPV over 3 to 5 years horizon. He was definitely typing away during our conversation, whether or not my inputs influence the conversation or dashboard he provides back to RAP or Pfizer, that's out of my control.

Expand

It’s hardly an ideal situation when shareholders know far more about a Company’s value than its Board does. At least it will result in a better educated Board going forward.

RAP Price at posting: 19.3¢ Sentiment: Buy Disclosure: Held
26 Upvote

2 Great analysis

Reply

Top Stories

Week 33 Wrap: US recession fears forgotten; RBNZ’s surprise rate cut; more iron ore trouble

SVL

Court of Appeal upholds environmental group's challenge to Silver Mines Ltd's Bowden project

IMD

IMDEX to receive $10M in out-of-court settlement with Boart Longyear over downhole tool patent

Bitcoin: Current State of Play & Where to Next | Swyftx

VTM

Victory Metals dips -8% even as company set to grow heavy REE resource at North Stanmore

EQR

EQ Resources transitions historic Mt Carbine tungsten mine to owner-operator system

ARD

Argent begins search for VMS mineralisation at Kempfield Cu-Pb-Zn-Au-Ag play in NSW

WNX

Wellnex sees first special access scheme prescriptions for new Wellness Life brand

M2R

EIS co-funded campaign sees Miramar kick off maiden drilling at Bangemall, Gascoyne WA

Emerald & Azure score Digger & Dealer awards

There are more pages in this discussion • 44 more messages in this thread...

First 423 Last

Add RAP (ASX) to my watchlist

Valuing ResApp Health, page-423

Top Stories

Week 33 Wrap: US recession fears forgotten; RBNZ’s surprise rate cut; more iron ore trouble

Court of Appeal upholds environmental group's challenge to Silver Mines Ltd's Bowden project

IMDEX to receive $10M in out-of-court settlement with Boart Longyear over downhole tool patent

Bitcoin: Current State of Play & Where to Next | Swyftx

Victory Metals dips -8% even as company set to grow heavy REE resource at North Stanmore

EQ Resources transitions historic Mt Carbine tungsten mine to owner-operator system

Argent begins search for VMS mineralisation at Kempfield Cu-Pb-Zn-Au-Ag play in NSW

Wellnex sees first special access scheme prescriptions for new Wellness Life brand

EIS co-funded campaign sees Miramar kick off maiden drilling at Bangemall, Gascoyne WA

Emerald & Azure score Digger & Dealer awards

Featured News